上市筹备 · 2025-12-29

How Share Award Schemes Impact Your Income Statement Before an IPO

The Hong Kong Stock Exchange (HKEX) issued its 2024 annual review of listing applications in Q1 2025, revealing that over 40% of rejected or returned Main Board prospectuses contained material deficiencies in the accounting treatment of equity-settled share-based payments. For CFOs and company secretaries at companies targeting a 2025-2026 listing window, this statistic is a direct regulatory red flag. The HKEX Listing Division, under its enhanced pre- vetting procedures effective January 2025, now requires sponsors to provide a detailed breakdown of share award scheme expenses within the three financial years preceding the listing application. The specific rule, codified in HKEX Listing Rules Chapter 9, Practice Note 21, mandates that all share-based compensation granted within 12 months of the listing date must be expensed in full, with no option for capitalisation. This creates a direct and often material impact on the income statement during the critical pre-IPO profitability test period. A company that granted 10 million share options to its founding team at a strike price of HKD 1.00 per share, when the fair value per option was HKD 5.00, would need to recognise a cumulative expense of HKD 40 million over the vesting period—an amount that can single-handedly push a company below the Main Board profit requirement of HKD 35 million for the most recent year under Rule 8.05(1)(a). This article dissects the mechanics, the regulatory traps, and the strategic levers available to manage this impact.

The accounting treatment for share award schemes is governed by Hong Kong Financial Reporting Standard 2 (HKFRS 2), “Share-based Payment,” which is substantively converged with IFRS 2. For a pre-IPO company, the core principle is that goods or services received in exchange for equity instruments must be measured at their fair value and recognised as an expense over the vesting period. The standard applies to all grants of shares, share options, or share appreciation rights to employees, directors, and even non-employees such as consultants or suppliers.

Fair Value Measurement at Grant Date

The most critical operational decision is the determination of the fair value of the equity instruments at the grant date. For share options, HKFRS 2 paragraph 17 requires the use of an option pricing model, with the Black-Scholes-Merton model being the most common for private companies due to its relative simplicity. The model inputs must be objectively supportable: the risk-free interest rate (typically the Hong Kong Exchange Fund Notes yield for a tenor matching the option life), the expected volatility (often derived from a comparable listed company’s historical volatility, as the company itself has no trading history), the expected dividend yield, and the expected life of the option.

A practical example illustrates the scale of the impact. A pre-IPO technology company granted 5 million share options to its senior engineers on 1 January 2024, with a vesting period of 3 years. The grant date fair value per option, calculated using Black-Scholes, was HKD 8.50. The total expense over the three-year vesting period is HKD 42.5 million. Under HKFRS 2 paragraph 15, this expense is recognised on a straight-line basis over the vesting period, meaning HKD 14.17 million per year. For a company targeting a Main Board listing in 2026, the profit test for the 2025 financial year—the most recent full year before the application—would be reduced by this HKD 14.17 million expense. If the company’s pre-share-based compensation profit was HKD 45 million, the reported profit falls to HKD 30.83 million, below the HKD 35 million threshold.

The Modification and Cancellation Trap

HKFRS 2 paragraphs 26-29 impose strict rules on modifications, cancellations, and settlements of share-based payment arrangements. A common pre-IPO scenario is the acceleration of vesting or modification of terms to align with the listing timeline. If a company modifies the vesting conditions of an existing award—for example, reducing the vesting period from 5 years to 2 years to ensure all awards vest before the IPO lock-up—the incremental fair value must be recognised immediately.

HKFRS 2 paragraph 27 states that the incremental fair value is the difference between the fair value of the modified equity instrument and the original equity instrument, both measured at the modification date. This incremental amount is expensed immediately, with no spreading over the remaining vesting period. A company that modifies 2 million options, each with an incremental fair value of HKD 3.00, would recognise an immediate expense of HKD 6 million in the year of modification. This can be a significant unplanned hit to the income statement in the year the company most needs to demonstrate profitability.

Regulatory Scrutiny from the HKEX Listing Division

The HKEX Listing Division’s approach to share-based compensation has become markedly more aggressive since the 2023 revision to the Listing Rules, particularly in the context of the “profit test” track under Rule 8.05. The division now routinely requests a “share-based compensation schedule” covering the entire track record period, typically three financial years, plus any grants made between the end of the track record period and the date of the listing application.

The “Recurring and Non-Recurring” Distinction

The HKEX has issued guidance through its “Listing Decision” series, specifically LD43-2013 and LD115-2017, which clarify that share-based compensation expenses are generally considered “recurring” in nature for the purpose of assessing a company’s ability to meet the profit test. This is a critical distinction because the profit test under Rule 8.05(1)(a) requires the company to show that the profit attributable to shareholders is “not derived from non-recurring items.”

The Listing Division’s position, as articulated in LD115-2017, is that share-based compensation arising from regular, ongoing employee incentive schemes is a recurring expense. Only one-off grants, such as a single grant made to a key executive upon joining, may be treated as non-recurring, and even then, the burden of proof rests with the sponsor and the company. A company that has a history of annual share option grants will find it nearly impossible to argue that the expense is non-recurring. The practical consequence is that the expense must be deducted from the profit figure used to satisfy the HKD 35 million threshold.

The “12-Month Rule” and Its Impact on Pre-IPO Grants

HKEX Listing Rules Chapter 9, Practice Note 21, paragraph 4.2, imposes a specific rule for share awards granted within 12 months of the listing date. These awards must be treated as “in substance” relating to the pre-IPO period, meaning the full expense must be recognised in the pre-IPO financial statements, even if the vesting period extends beyond the listing date.

This rule directly counters any attempt to push expenses into the post-IPO period. Consider a company that grants share options to its CEO on 1 June 2025, with a listing date of 1 December 2025. The options have a 4-year vesting period. Under the 12-month rule, the full fair value of the options—say, HKD 20 million—must be expensed in the 2025 financial year, even though only 6 months of the vesting period has elapsed. This can completely eliminate the profit for that year. The HKEX’s logic is that these grants are made in anticipation of the listing and therefore relate to the pre-IPO service period.

Given the regulatory and accounting constraints, the structuring of a share award scheme must begin at least 24 months before the intended listing date. The goal is to minimise the income statement impact in the track record period while still providing adequate incentives for key personnel.

Grant Timing and Vesting Schedules

The most effective strategy is to front-load grants into periods that fall outside the three-year track record. If a company intends to list in 2026, the track record period will cover the financial years ending 2023, 2024, and 2025. Any share awards granted before 1 January 2023 will have their expense fully recognised before the track record period begins, provided the vesting period is complete. For awards granted during the track record period, the expense must be recognised over the vesting period, but the company can control the timing by choosing a grant date early in the period.

A company that grants options on 1 January 2023, with a 3-year vesting period, will recognise the expense evenly over 2023, 2024, and 2025. This is manageable if the total expense is within the profit buffer. However, a grant made on 1 December 2025, with a 3-year vesting period, would result in only one month of expense in the 2025 financial year, but the remaining 35 months of expense would be recognised in the post-IPO period. The catch is the 12-month rule: if the listing occurs within 12 months of this grant, the full expense must be recognised in the pre-IPO period anyway. The safe harbour is to ensure that all grants are made at least 12 months before the intended listing date.

Use of Performance Conditions

HKFRS 2 permits the use of performance conditions, both market-based and non-market-based, which can affect the expense recognition. A non-market performance condition, such as a revenue target or an EBITDA target, is taken into account when estimating the number of options that will ultimately vest. Under HKFRS 2 paragraph 21, the company must estimate the number of options expected to vest at each reporting date, based on the probability of achieving the performance condition.

This creates a mechanism to reduce the expense in the early years of the track record. If the performance condition is challenging and the probability of achievement is assessed at 40% at the end of 2024, the expense for that year would be based on 40% of the total grant. If the condition is met in 2025, the cumulative expense is trued up in that year. This can smooth the income statement impact, provided the performance condition is objectively verifiable and not designed solely to manipulate the expense. The HKEX will scrutinise such conditions closely under Listing Rule 2.03, which requires the listing to be in the “interests of the investing public.”

Cash-Settled Alternatives

For companies with sufficient cash reserves, a cash-settled share appreciation right (SAR) scheme can be a strategic alternative. Under HKFRS 2 paragraphs 30-33, cash-settled share-based payments are measured at the fair value of the liability, which is remeasured at each reporting date until settlement. The expense is recognised over the vesting period, but the liability is marked to market.

The key advantage for a pre-IPO company is that the liability is measured based on the current fair value of the shares, which for a private company is typically lower than the expected IPO price. If the company’s pre-IPO valuation is HKD 10 per share, the SAR expense will be based on HKD 10, not the HKD 20 expected IPO price. This reduces the expense in the track record period. However, the liability will increase post-IPO as the share price rises, creating a future charge. This trade-off must be modelled carefully. The HKEX requires full disclosure of SAR schemes in the prospectus, including sensitivity analysis to share price changes.

The prospectus disclosure requirements for share award schemes are extensive and are governed by HKEX Listing Rules Chapter 11, Appendix D1A, paragraph 27. The prospectus must include a description of the scheme, the number and class of shares subject to the scheme, the basis of determining the exercise price, the vesting period, and the total expense recognised in each of the three financial years in the track record.

The Sponsor’s Role in Verifying Fair Value

The sponsor is required to perform due diligence on the fair value of the share-based payments. Under the SFC’s Code of Conduct for Persons Licensed by or Registered with the Securities and Futures Commission, paragraph 17.6, the sponsor must ensure that the valuation methodology is appropriate and that the key inputs are supportable. For a private company, this often means the sponsor will commission an independent valuation of the company’s shares as at each grant date.

The sponsor will also review the company’s historical practice of granting share awards. If the company has a pattern of making large grants shortly before the listing date, the sponsor must assess whether these grants are “in contemplation of the listing” and therefore subject to the 12-month rule. The sponsor’s report to the HKEX must include a specific section on share-based compensation, and any material deficiencies will result in the listing application being returned.

Impact on Pro Forma Financial Information

The prospectus must include pro forma financial information that adjusts the historical financial statements for the effects of the listing, including the impact of any share award schemes that will be implemented post-listing. Under HKEX Listing Rules Chapter 4, paragraph 4.29, the pro forma adjustments must be clearly described and supported by a letter from the reporting accountant.

A common adjustment is the recognition of a new share option scheme adopted immediately before listing. If the scheme grants 10 million options at an exercise price equal to the IPO price, the pro forma income statement for the most recent financial year must include the expected expense for the first year of the scheme, even though the scheme did not exist during that historical period. This adjustment can significantly reduce the pro forma profit, which is the figure most analysts will use to value the company. The adjustment must be calculated using the same fair value methodology as the historical grants.

Actionable Takeaways for Pre-IPO Companies

Begin the share award scheme audit at least 18 months before the intended listing date, modelling the full expense impact under HKFRS 2 for all existing and planned grants to ensure the profit test thresholds under HKEX Listing Rule 8.05(1)(a) can be met with a minimum 20% buffer.
Ensure all share award grants are made at least 12 months before the listing date to avoid the immediate full-expense recognition trap under Practice Note 21, and document the business rationale for each grant to demonstrate it is not “in contemplation of the listing.”
Engage an independent valuer to determine the fair value of shares at each grant date, using a methodology consistent with the company’s pre-IPO valuation, and ensure the sponsor reviews and signs off on the valuation inputs as part of the SFC Code of Conduct paragraph 17.6 due diligence.
Structure performance conditions that are objectively verifiable and linked to the company’s business plan, as these can reduce the recognised expense in the early years of the track record and withstand HKEX scrutiny under Listing Rule 2.03.
Prepare a detailed share-based compensation schedule for the full track record period, including grants made after the balance sheet date, and have the reporting accountant review the expense recognition to ensure compliance with HKFRS 2 and the HKEX’s Listing Decisions LD43-2013 and LD115-2017.